Does Mounjaro (Tirzepatide) Cause Glaucoma?
No, Mounjaro (tirzepatide) does not cause glaucoma and may actually reduce the risk of developing primary open-angle glaucoma (POAG) and ocular hypertension compared to other diabetes medications.
Evidence from FDA Drug Labeling
The official FDA prescribing information for Mounjaro does not list glaucoma as a known adverse effect 1. The documented ophthalmic concern relates specifically to diabetic retinopathy complications in patients with pre-existing diabetic retinopathy, which is attributed to rapid glucose improvement rather than a direct drug effect 1.
Clinical Guidelines Position
Recent 2025 clinical practice guidelines for obesity and diabetes management extensively discuss tirzepatide's side effect profile, listing gastrointestinal issues, gallbladder disease, and pancreatitis risk, but make no mention of glaucoma as a concern 2, 3.
Notably, a 2016 AACE guideline specifically addresses glaucoma risk with weight-loss medications, recommending that liraglutide (a GLP-1 RA like tirzepatide) should be preferred for patients with glaucoma history or risk, while phentermine/topiramate should be avoided 4. This suggests the GLP-1 RA class, which includes tirzepatide's mechanism, has no established glaucoma association.
Emerging Protective Evidence
Most importantly, recent research suggests tirzepatide may actually protect against glaucoma. A 2025 retrospective cohort study of 41,849 matched patients found tirzepatide was associated with:
- 50% reduced risk of POAG (RR 0.50,95% CI 0.34-0.74)
- 41% reduced risk of ocular hypertension (RR 0.59,95% CI 0.40-0.88)
- 46% reduced need for glaucoma treatment (RR 0.54,95% CI 0.45-0.64)
compared to selective GLP-1 RAs 5.
Important Distinction: NAION vs. Glaucoma
There have been case reports of non-arteritic anterior ischemic optic neuropathy (NAION) with tirzepatide 6, 7, but this is a completely different condition from glaucoma:
- NAION is an acute vascular event causing sudden optic nerve ischemia
- Glaucoma is a chronic progressive optic neuropathy related to intraocular pressure
- The NAION cases may be related to rapid glucose correction rather than direct drug toxicity 7
- NAION signals remain under investigation with disproportionality analysis showing "probable" association but rare occurrence 6
Clinical Recommendations
For patients with glaucoma or at risk:
- Tirzepatide can be safely used and may offer protective benefits 5
- Monitor for diabetic retinopathy progression if pre-existing retinopathy is present 1
- Be aware of NAION as a rare but serious event (distinct from glaucoma) 6, 7
Common pitfall: Confusing NAION reports with glaucoma risk. These are separate ophthalmic conditions with different pathophysiology and risk profiles.